6月11日，诺华盘前上涨3.11%，报152.71美元/股，成交额113.54万美元。
消息面上，诺华近期利好密集：公司宣布其肌营养不良实验性疗法del-brax的I/II期研究达到主要终点及关键次要终点；同日，诺华与Orionis Biosciences达成总额超14亿美元的分子胶药物合作；此外，泰菲乐联合迈吉宁新增适应症获中国国家药监局批准，用于BRAF V600E突变阳性的分化型甲状腺癌治疗。多重管线进展叠加，提振市场对公司研发管线价值的预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.